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Blood-testis barrierThe idea that men should participate in family planning by playing an active role in contraception has
becomemore acceptable in recent years. Up to the present the condom and vasectomy have been themain
methods of male contraception. There have been and continue to be efforts to develop an acceptable hor-
monal contraceptive involving testosterone (T) suppression. However the off target affects, delivery of the
analogs and the need for T replacement have proven difﬁcult obstacles to this technology. Research into the
development of non-hormonal contraception formen is progressing in several laboratories and this will be
the subject of the present review. A number of promising targets for the male pill are being investigated.
These involve disruption of spermatogenesis by compromising the integrity of the germinal epithelium,
interfering with sperm production at the level of meiosis, attacking speciﬁc sperm proteins to disrupt fer-
tilizing ability, or interfering with the assembly of seminal ﬂuid components required by ejaculated sperm
for acquisition of motility. Blocking contractility of the vas deferens smoothmuscle vasculature to prevent
ejaculation is a unique approach that prevents sperm from reaching the egg.We shall note the lack of inter-
est by big pharma with most of the support for male contraception provided by the NIH.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Family planning, or contraception has generally been the
responsibility of the female partner in a relationship. After all, it’s
the woman who gets pregnant. This doesn’t mean that men can’t
or shouldn’t accept the contraceptor’s role. In fact, in some partner-
ships this becomes a necessity, if the woman is unable for health
reasons to use the birth control pill. Presently, there is a concerted
research effort to develop a male pill.
That man realized he provided the seed that produced the baby
dates to ancient times as evidenced by the reference in Genesis
38:9 to Onan spilling his seed on the ground to avoid impregnating
his brother’s widow. Awareness that some natural products could
decrease male fertility also traces to antiquity. The use of plants
stems from at least the ﬁrst century CE when Dioscorides included
that hemp seeds ‘extinguished conception’ in his extensive compi-
lation of natural materials for medicinal use.1 This documents
what may have been a long history of attempts to use plant seeds,
leaves and extracts for birth control and perhaps the beginning of
men taking an active role in this process. In fact, it is likely that
contraception, whether used by women or men, was not a topic
for public discussion in polite society until the advent of the ‘‘pill’’
for use by women. It was not long after this that sex came out from
under the covers. And then the idea of sharing the contraceptiveburden, at least in a stable relationship, motivated research into
developing the ‘male pill’.
Directed research in male contraceptive development is rela-
tively new. It is also fraught with difﬁculties because the goal is
to provide a drug that can be used safely by healthy individuals
of reproductive age (the fact that the same is true for a woman
doesn’t seem to have been a real problem). The burden for demon-
stration of safety, efﬁcacy, and reversibility by regulatory agencies
and the consumer is high. This burden may even include the assur-
ance of no deleterious effects to the future offspring. This perhaps
is a major reason that ‘Big Pharma’ rapidly lost interest in pursuing
a birth control pill for men. As a consequence, the National
Institutes of Health (NIH) is the major, if not sole source of funding
to develop a male pill in the United States. Perusal of the 124
currently open clinical trials retrieved under the search term
‘contraception’ that are registered at the National Library of
Medicine revealed only one that was concerned with the develop-
ment of a male contraceptive drug, dimethandrolone undecanoate,
discussed below.2,3 The lack of pharmaceutical support can be
argued to have more to do with the slow progress in this ﬁeld than
anything else.
In the United States, condoms and vasectomy are the only two
methods of contraception available for use by men. Of these two
methods, only condom use is reliably reversible. Condoms serve
as exterior barriers to block fertilization and have in one form or
another been used for perhaps thousands of years.4 Not only are
condoms widely available, even in rather esoteric shapes and sizes,
but nowadays packages are prominently displayed in pharmacies
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ure rate for typical use is as high as 18%.5 Condoms also serve the
dual function of protecting against STD’s, and should be used with
or without the pill in casual sexual relationships.
Vasectomy, an invasive procedure, is used by only an estimated
6% of U.S. couples.6 Efﬁcacy is extremely high and complications
are relatively rare. Vasovasostomy (re-anastomoses of the vas) by
skilled surgeons is relatively straight forward, with patency rates
(return of sperm to semen) ranging from 70–95% dependent on
the procedure and time elapse since vasectomy.7 Pregnancy rates
of the partner are considerably lower at 30–76%, which may reﬂect
a host of variables including the woman’s age. In addition, there is
evidence that vasectomized men develop antibodies to sperm that
lead to infertility which of course defeats the purpose of the vaso-
vasostomy. Therefore, vasectomy is not an ideal choice for men
who plan to have a family in the future. Cultural and other barriers
also contribute to its low level of use in the United States.6 The
prospect of developing a non-invasive, reversible, physically satis-
fying, and safe pharmaceutical contraceptive for use by men is
worthwhile. But ﬁrst we might ask why?
Nearly half of all pregnancies in the United States are unin-
tended.8 This statistic illustrates the urgent need to develop new
methods of male contraception and overcome uncontrolled fertil-
ity. While a variety of options are available for female contracep-
tion, there is no safe, effective, and reversible contraceptive drug
product in the market for men. There is however a rather startling
array of instructions for the preparation of homemade contracep-
tive brews for men available on the Internet. This unsubstantiated
collection must represent the need and interest of men seeking out
reversible contraceptive choices. It is astonishing, that in the 21st
century, the reversible contraceptive choices for a man differ little
from the ﬁrst century.
Development of a male contraceptive targeting the hormonal
control of spermatogenesis, consisting of a progestin and testoster-
one, is the most developed pharmaceutical option at this time,
though nothing will be on the market in the US in the near future.
The strategy is to down-regulate pituitary release of LH and FSH
resulting in decreased production of testosterone in the testis
and impaired spermatogenesis.9–12 Concerns about a hormonal
male contraceptive are raised by studies that have revealed an ar-
ray of physiological changes with short-term administration of tes-
tosterone derivatives that were undesirable. These included
metabolic disturbances such as weight gain, decreased HDL/LDL
ratios, and increased serum glucose levels. Acne, decreased libido,
reduced testis size, and mood changes have also been commonly
reported. In addition, a signiﬁcant percentage of men do not
achieve sufﬁcient suppression of spermatogenesis for contracep-
tion and, although not understood, this is inﬂuenced by ethnic
background.13 The need to routinely inject some formulations is
likely to reduce acceptance by many men. There is a promising re-
cent report of a clinical trial that combined delivery of testosterone
(T) and nestorone (a nonandrogenic progestin) by transdermal gels
for the suppression of spermatogenesis.14 Transdermal gels are a
more acceptable method of delivery and efﬁcacy across diverse
ethnic groups was achieved with 88–89% of treated men achieving
sperm concentrations below 1 million/ml. The authors concluded
that a combination of daily NES+T gels suppressed sperm concen-
tration to contraceptive levels, with minimal adverse effects, and
may be further studied as a male transdermal hormonal contracep-
tive. The same research group has phase 1 studies underway to as-
sess safety and tolerability of dimethandrolone undecanoate
(DMAU); an androgen with progestin activity.2,15
In addition to approaches based on the hormonal control of
spermatogenesis, there is a need to develop non-hormonal meth-
ods by identifying novel targets for contraceptive intervention.
We have no bias as far as hormones are concerned, but thediverse targets available for non-steroidal suppression of sper-
matogenesis hold the promise of development of an efﬁcacious
drug with minimal side effects and acceptable routes of delivery.
The remainder of this review will focus on the clinical and re-
search progress towards development of non-hormonal contra-
ceptive methods.
There are a number of exciting, potential drug targets that are
being pursued. The challenge is that the delivery must be simple
and that the effects of the drug be non-toxic, speciﬁc to the target
and reliably reversible in affecting fertility. Levels of attack are the
testes, epididymis, and spermatozoa. The goal may be to either
suppress spermatogenesis (i.e., reduce sperm counts) or to render
sperm non-functional. That is, in order to reach the egg, sperm
must be motile and in order to penetrate the outer coat, the zona
pellucida of an egg, sperm must undergo a maturation process,
called capacitation, in the female reproductive tract. All these steps
must take place before fertilization can occur providing multiple
targets for contraceptive intervention.
Drug discovery is a complicated process requiring collabora-
tions with medicinal chemists, structural biologists, practitioners
in pharmacokinetics, and in this arena, reproductive biologists.
Medicinal chemistry procedures are well established, but complex
and costly. The process involves target identiﬁcation and high
throughput screens (HTS) to identify active compounds. Require-
ments for activity, selectivity, and physicochemical properties
must be supported by bioassay and computational methods and,
where possible, biophysical measurements and protein crystallog-
raphy. HTS triage (selection of compounds for follow-up) requires
that each compound that is screened must also be tagged as a con-
ﬁrmed active, a non-conﬁrmed active, or an inactive compound.
Because most of the data collected is proprietary the information
about targeting described below is limited. Figure 1 shows the
chemical structures of the non-steroidal compounds with potential
for male contraception discussed below.
The mammalian testis is a dual function organ responsible for
maintaining the body’s hormonal homeostasis as well as being
the site of sperm production. Testosterone (T) is the most familiar
and important hormone for sexual behavior as well general phys-
ical well-being. There are no shortages of ads promoting T to not
only improve men’s sex lives but also enhance their business acu-
men and social behavior. Usually T levels decline with age and
there is research, which will not be addressed here, on such stud-
ies. The point in this context is that an endocrine method of birth
control in men, which affects hormonal balance must be carefully
adjusted and the difﬁculty in accomplishing the appropriate
treatment regime is one of the major complications in hormonal
intervention for male birth control. For this reason, an alternative
approach aimed at discovery of a non-androgenic compound to
disrupt sperm production or sperm function is attractive.
Vitamin A metabolism has long been considered as a target for
male contraception.16 Meiosis in both male and female germ cells
requires retinoic acid.17,18 Vitamin A deﬁcient rodents and retinoic
acid receptor (RAR) alpha knock-out mice are infertile in the
male.17,19 The phenotypic defects in spermiation are similar in both
models. Recently, a RAR antagonist (BMS-189453) that binds all
three RARs (a,b,c) has been studied for contraception in male
mice.20 It causes a failure of spermatid alignment and sperm re-
lease and is extremely effective, highly reversible, and shows low
off-target effects. This research is at the stage of trying to develop
an RARa-speciﬁc antagonist to minimize off-target effects.21 The
RARa-selective antagonists, BMS-189532 and BMS-195614
displayed selective activity in vitro, both compounds failed to
suppress spermatogenesis with oral administration to mice. These
investigators plan to build on these results, which they suggest
are crucial for designing new RARa-selective antagonists for
pharmaceutical application.
BMS-189453 BMS-189532 BMS-195614
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Figure 1. Structures of non-steroidal compounds under study for male contraception. Structures were obtained from the publications cited in discussion of each compound
below or the PubChem Compound Database at the National Center for Biotechnology Information.
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known to inhibit spermatogenesis in human beings upon oral
administration, however severe side effects occur when mixed
with alcohol consumption.22,23 The mechanism of action has re-
cently been shown to be at the level of inhibition of the aldehyde
dehydrogenase 1a2 (ALDH1a2) required for the conversion of vita-
min A to retinoic acid.24 The challenge in this research is to synthe-
size novel derivatives of WIN 18,446 that are speciﬁc for the testis
aldehyde dehydrogenase while inactive against ALDH2. Whether
this research is progressing to product development is unknown
because of the proprietary nature of data on analog research.
Achieving speciﬁcity between testis and somatic isoforms is a
common obstacle to almost any approach to a non-steroidal male
contraceptive that could be taken orally.
The impact of serendipity is apparent from the ﬁnding during
research for an anti-cancer drug that BRDT (murine, NCBI accession
#EDL20168.1) targets spermatogenesis. This is an exciting and rel-
atively recent observation. BRDT is a bromodomain protein mem-
ber of the BET family, and it binds acetylated histone 4 associated
with meiotic and post-meiotic chromosomes in sperm.25,26
Although named as testis-speciﬁc, it is also found in oocytes.27
Male mice homozygous for mutations in the ﬁrst bromodomainregion of BRDT were infertile, but otherwise appeared normal indi-
cating the speciﬁcity of this protein.28 Female mice appeared nor-
mal and were fertile. The small molecule, JQ1, a thieno-triazolo-1,
4-diazepine, was designed as a prototype for binding to the brom-
odomain in the BET protein family and is highly selective for this
speciﬁc bromodomain.29 There is recently published work on the
use of JQ1 as an i.p. daily injection, male contraceptive in mouse.30
Complete and reversible contraception was achieved in a small
group of male mice and histochemical analysis indicated that ef-
fects were at the level of spermatocyte to spermatid maturation
with a concomitant decrease in testicular volume. Off target effects
were not observed and circulating levels of FSH, LH and testoster-
one were normal. There were no observed effects on offspring sired
by males after treatment. Enthusiasm for this approach is tem-
pered, since the severe decrease in testicular size (40–70%) could
be unacceptable to many men.31 Further research is necessary to
achieve increased selectivity based on structure-function insights
from molecular recognition of bromodomain proteins by natural
ligands.
Sertoli cells comprise the somatic cell component of the germi-
nal epithelium and are responsible for maintaining the separation
of germ cells from the circulation by a blood testis barrier. Adjudin
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lonidamine.22,32,33 It disrupts the bridges between spermatids
and Sertoli cells thus perturbing sperm maturation. Although
highly effective and reversible in rodents, there are off-target ef-
fects in other organs such as liver that have essentially halted
investigations of the use of this formulation. Conjugation with a
portion of the FSHß subunit allows more speciﬁc targeting to the
testis, but increases cost. Delivery (injection) is less than optimal.
H2-gamendazole is another lonidamine derivative that has been
investigated as a non-steroidal male contraceptive with some
promise, but there are signiﬁcant concerns about toxicity and
reversibility in rodents.34,35 CDB-4022 is a chemically distinct com-
pound, an indenopyridine that also works at least in part in the
seminiferous epithelium to disrupt germ cell adhesion.36,37 Revers-
ibility is species dependent; high in primate models, but low in
rats.33
The spermatozoan can be described as the DNA containing cell
driven by a molecular motor toward an oocyte in the female repro-
ductive tract. As such it contains tightly packaged genetic material
in a nucleus propelled by a sleek ﬂagellum, which houses the en-
ergy generating reaction mechanism for motility. The sperm of
many species including rodent and man rely on aerobic glycolysis
for ATP production. Just as the sperm is a unique cell, it also con-
tains sperm speciﬁc isoforms of many of the glycolytic enzymes.
Mature spermatozoa exhibit high levels of aerobic glycolysis and
convert glucose into pyruvate with concomitant production of
ATP. Targeting sperm speciﬁc glycolytic enzymes represents a no-
vel approach to male contraception. Several in vitro studies pro-
vided evidence that glucose metabolism has an essential role in
production of the ATP required for spermmotility, hyperactivation,
and capacitation.38–41 This conclusion is consistent with the severe
defects in sperm progressive motility and in male infertility shown
to result from the targeted disruption of glycolytic enzymes.
Inactivation of the gene for the sperm-speciﬁc glycolysis path-
way enzyme glyceraldehyde 3-phosphate dehydrogenase (Gapdhs)
dramatically reduced the level of ATP in sperm.42 Early studies of
a-chlorohydrin provided the ﬁrst experimental evidence that GAP-
DHS can be selectively inhibited. Those studies showed that the
GAPDH step of glycolysis in sperm was inhibited by S-3-chlorolact-
aldehyde, the active metabolite of a-chlorohydrin and related
compounds, even though it was not known that the sperm have
a unique isozyme. Although there were side effects at high doses,
sperm glycolytic activity and motility were inhibited at concentra-
tions that did not inhibit the somatic isozyme in other tissues.
Targeting this isozyme became knowledge-based with the high-
resolution crystal structures available for human GAPDHS and
GAPDH. Comparison of these structures revealed that there are
two regions near the active site that are different between the iso-
zymes and may contribute to differences in catalytic properties.43
These regions may be exploited for developing selective inhibitors.
Compounds showing partial selectivity by inhibiting sperm glycol-
ysis (as measured by lactate production) and sperm motility, par-
ticularly hyperactivation may provide viable leads to drug
development.44
The essential role of glucose metabolism in sperm function is
also demonstrated by the severe defects in sperm progressive
motility and in male infertility shown to result from the targeted
disruption of Ldhc.45 LDH-C4 was thought to be the only member
of the LDH family active in spermatozoa.46,47 A series of studies
have shown that LDH-A4 also is present and localized to the prin-
cipal piece of the sperm ﬂagellum along with LDH-C4 and other
glycolytic enzymes.45,48–51 However, LDH-A4 is bound tightly to
the ﬁbrous sheath while LDH-C4 is abundant throughout the
cytoplasm of the sperm principle piece.48,50 These differences in
localization suggest that LDH-C4 may be required for the initial
ATP consuming steps of glycolysis while LDH-A4 completes at leastpartially the ATP generating reactions necessary for motility and
capacitation.
LDHC has been proposed as a valid target for a contraceptive
drug. Despite the negligible structural diversity between the LDH
isozymes, there are very signiﬁcant dissimilarities in the kinetic
properties of each form that become even more pronounced for
the sperm-speciﬁc LDH-C4. LDH-C4 has kinetic properties very dif-
ferent from the ﬁve isozymes that are derived from the association
of A and B subunits.52 LDH-C4 has high thermostability and a broad
substrate speciﬁcity, including the ability to metabolize other a-
ketoacids almost as efﬁciently as lactate; a property that could
be exploited in drug development.53–56 These differences in cata-
lytic properties, in abundance in germ cells, and in localization in
spermatozoa support the hypothesis that LDH-C4 has unique struc-
tural and functional properties that are amenable to production of
isozyme speciﬁc inhibitors. The discovery that LDH-C4 is required
for male fertility in mice parallels observations that LDH-C4 was
undetectable in semen samples from a subset of men presenting
at a fertility clinic.45,57 These men produced normal numbers of
sperm that initially were motile, but soon became poorly motile
or non-motile. Large-scale gene expression studies in humans also
correlate with reduced LDHC expression with infertility.58 Hence,
inactivating mutations in the human LDHC gene might negatively
impact human sperm function. Chemical inhibition of LDH-C4 as a
target for male contraception by disabling sperm fertilizing capac-
ity needs to be explored.
The recent establishment of patch-clampmethodology in whole
sperm has been essential for identiﬁcation of functional ion chan-
nels and has opened up a new class of targets to inactivate
sperm.59 A voltage-gated calcium channel restricted to sperm is
constructed using four gene products: CatSper (sperm-associated
cation channel) 1–4. Three other gene products are associated with
the CatSper complex. This channel is regulated by pH, prostaglan-
din, and the progesterone produced by cumulus cells associated
with the egg in the oviduct in human.60,61 All four of the CatSper
proteins 1-4 are required for fertility in the male and the channel
is important for sperm capacitation, hyperactivation, and egg pen-
etration.62,63 The speciﬁcity to sperm, the lack of redundancy, and
the function at the ﬁnal stages of sperm maturation make these
proteins ideal targets for contraceptive development and studies
for both vaccine and pharmaceutical development have been
reported.64 HC-056456 was reported to speciﬁcally block CatSper
channel activity in whole sperm, using a high-throughput adapt-
able assay.65 The drug inhibited hyperactivation of the sperm.
The high-blood pressure medication and calcium channel blocker,
nifedipine, has been shown to cause reversible infertility in some
men.66 It is not clear if this is by action on the CatSper channel,
however its lack of speciﬁcity for sperm exclude it from develop-
ment for contraception.
A spermatozoa-speciﬁc pH-dependent potassium channel is en-
coded by the Slo3 gene and gene knock-out render mice infer-
tile.64,67 This channel represents another potential target for a
pharmacological contraceptive. The sperm Na+/H+exchanger
(sNHE, Slc9c1 gene in mouse) is essential for sperm motility as
demonstrated in knockout mice and has been widely discussed
as a candidate target for male contraception.68 Although the
Na,K-ATPase is ubiquitously expressed, the polypeptide responsi-
ble for the ATPase activity has a sperm-speciﬁc isoform, termed
Na,K-ATPase a4.69 Male knockout mice for the Atp1a4 gene encod-
ing a4 are infertile and produce sperm with defective morphology
and motility. The speciﬁcity of the a4 polypeptide to differentiated
spermatozoa makes it an excellent target for reversible
contraception.
EPPIN, an epididymal protease inhibitor, was identiﬁed in a hu-
man epididymal cDNA library and is the target of compound
screening as well as an antigen for vaccine development.70 EPPIN
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the semen coagulating protein semenogelin I (SEMGI) and thus
modulates sperm motility. The protein-protein interaction sites
on EPPIN have been dissected and speciﬁc amino acid residues re-
quired for SEMGI binding have been identiﬁed, providing evidence
that EPPIN is a prime target for contraceptive compound
development.71
A wealth of data from expression proﬁling, knock-out mice,
endocrine disrupters, and RNAi screens is yielding identiﬁcation
of many new candidate targets for male contraceptive develop-
ment.72–77
The testis-speciﬁc protein adenine nucleotide translocase
(ANT4) is a member of the ANT protein family involved in ADP-
ATP translocation to mitochondria. Disruption of Ant4 leads to
meiotic arrest at the leptotene stage during spermatogenesis.78
Chromatin modifying enzymes, including Dnmt3 and the PRC2
complex, play roles in the regulation of Ant4 gene expression that
possibly could be exploited as a contraceptive approach.79,80
Further, through an evolutionary genomics approach, Ant4 has
been proposed to have a specialized function in mammalian male
fertility beyond meiosis.81 The goal is to identify candidate
compounds that can selectively inhibit ANT4 activity over the
other ANT family members. One approach might be to disrupt
the protein-protein interaction of ANT4 and LDHC.82
The testis speciﬁc serine threonine kinases 1 & 2 are closely re-
lated genes that have recently been validated as male contracep-
tive targets.83 These proteins are expressed selectively in the
testis in post-meiotic spermatids and knockout of Tssk 1 & 2 causes
male infertility. A search for inhibitors of these proteins is
underway.
The observation of testis/sperm speciﬁc expression is useful
only for the most preliminary identiﬁcation of a protein as a candi-
date. Validation of candidates is laborious and expensive–knockout
in the mouse being the most rigorous proof of a role in fertility.
Development of compounds that affect the activity of these vali-
dated candidate proteins and studies to determine contraceptive
efﬁcacy, reversibility, and safety are essential. This conceptual ap-
proach has been in place for many years now, however little pro-
gress on moving compounds to clinical trials has been made. An
attack on the delivery system has been proposed that would pre-
vent or reduce the number of sperm deposited into the vagina.
Sperm propulsion from the cauda epididymis to the urethra in suf-
ﬁcient numbers for fertilization requires autonomic nervous sys-
tem control of smooth muscle contractions in the walls of the
vas deferens. Contraction of the smooth muscle cells surrounding
the vas deferens is mediated by P2X-purinoceptors in response
to ATP and alpha1A-adrenoceptors in response to noradrenaline.
84–86 The recent report that male mice homozygous for null alleles
of genes encoding both of these proteins are infertile suggests a un-
ique contraceptive target.87 Male mice were rendered infertile
without effects on sexual behavior or adverse system-wide
physiological consequences. The alpha1A-adrenoceptors and
P2X1-purinoceptors are widely distributed and particularly impor-
tant in vascular control. Reduction in resting blood pressures of the
mutant mice was observed but not considered a serious off target
effect by the investigators of this study. The fact that a combined
inhibition of both proteins is required for near 100% efﬁcacy makes
the search for a safe drug combination, as well as approval by reg-
ulatory agencies for human use, complicated at best. While libido
(as in the mouse model) may not be reduced, the potential for de-
creased ejaculate may impact perception of orgasmic satisfaction
for some men. This indeed was suggested in a pilot study adminis-
tering an alpha1A-adrenoceptors blocker to healthy men.88 Never-
theless this is an innovative approach in which neither sperm
production nor the sperm itself is targeted.An important question to raise is whether the search for a male
contraceptive is a cost-effective way to spend limited research dol-
lars? Although the approach is expensive, research to block fertility
will also contribute to our understanding of the causes of male
infertility, which are multiple and complex. A greater understand-
ing of the mechanism of male fertility is essential in order to ad-
dress the medical needs of the 1 in 20 men of reproductive age
who are infertile. This will, in turn, provide for a more mechanistic
approach to contraception. The current increase in information
about the cellular and molecular mechanisms involved in sper-
matogenesis, which will be further accelerated by advances in
genomics and proteomics can lead to identiﬁcation of novel targets
for contraceptive intervention.
There are a great variety of targets and strategies that have al-
ready been proposed for non-steroidal male contraception and
more can be developed.22,66,89–91 Many of these approaches have
run into difﬁculties with toxicity, lack of reliable reversibility,
unacceptable delivery methods, lack of efﬁcacy, and/or expense,
however progress is being made as demonstrated by the studies
cited.
A number of targets have been identiﬁed and the challenge re-
mains to develop compounds that fulﬁll the demanding require-
ments for a broadly acceptable male contraceptive. Any
pharmaceutical male contraceptive will need to be reversible in or-
der to appeal to the largest cross-section of men that will make this
a marketable product. Although several of the compounds de-
scribed above show reversibility in studies using small numbers
of animals, these studies were all done over a relatively small per-
centage of the reproductive life span of the test animal. In human
populations, these drugs would potentially be used for years before
the subject might want to regain fertility. Compounds (and pro-
posed targets) that function early in the spermatogenesis pathway
can, or may be expected to, cause signiﬁcant tissue remodeling in
the testis. The long-term consequences of such remodeling must be
of concern. In addition to efﬁcacy and reversibility, long-term
safety for the patient, and perhaps to potential future offspring,
is also required.
The shotgun approach with small studies aimed at multiple
targets, perhaps because of limited funding, is not likely to
advance the cause in a timely fashion. It appears that most
pharmaceutical industry research stopped by 2009.23 The
complexity of the research needed perhaps provided too little
return (‘bang for the buck’) economically. The fact that NIH
has a Contraceptive Discovery and Development Branch
suggests an awareness of the need for basic research into
new methods of birth control. Unfortunately, contraception is
not considered a disease and therefore such research is under-
funded at best. There remains a critical need for additional
contraceptive options, including those that target male
gametes. It is not unreasonable to suggest that men and
women share the contraceptive burden. The signiﬁcant issue
addressed by these various research projects is the urgent need
to develop new methods of male contraception and overcome
uncontrolled fertility, one of the most pressing public health
challenges of the 21st century.
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